CLINICAL CASE OF SUCCESSFUL 10-YEAR AMBRIZENTAN TREATMENT OF THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

Idiopathic pulmonary arterial hypertension (IPAH) is a rare cardiovascular disease of unknown etiology, characterized by pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) increase due to pronounced remodeling of small pulmonary arteries and arterioles, with progressive deterioration and the rapid development of right ventricle failure. The key pathogenetic feature is the endothelial dysfunction, which leads to the development of vasoconstriction, thrombosis in situ, proliferative and inflammatory changes in the lung microvasculature. Optimization of drug therapy is associated with the clinical implementation of highly effective pathogenetic drugs which act on the main disease targets - activation of endothelin-1 (ET-1) system, the lack of endogenous prostacyclin and nitric oxide. The role of ET-1 as a powerful vasoconstrictor that induces cell proliferation and differentiation, production of cytokines, growth factors, biologically active substances. Endothelin receptor antagonists (ERA) represents the important class of PAH-specific therapy, including two non-selective ERAs-nonselective bosentan and selective ambrizentan. Presented clinical case demonstrates the long-term reliable efficacy and safety of ambrizentan for 10 years in the IPAH patient with the baseline functional class III (WHO).

idiopathic pulmonary hypertension, endothelin-1, endothelin receptor antagonists, ambrisentan, идиопатическая лёгочная гипертензия, эндотелин-1, антагонисты рецепторов эндотелина, амбризентан

1. Чазова И.Е., Авдеев С.Н., Царева Н.А. и др. Клинические рекомендации по диагностики и лечению лёгочной гипертензии. Терапевтический архив 2014;86(9):4-23

2. Galie N., Hoeper M.M., Humbert M. et al. ESC Committee for Practice Guidelines. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)., endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-2537

3. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121: 2045-2066

4. D’Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115:343-349

5. Dupuis J., Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-415

6. Galie N., Manes A., Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61:227-237.

7. Ito H., Hirata Y., Hiroe M., et al. Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 1991; 69:209-215.

8. Stewart D.J., Levy R.D., Cernacek P. Increased plasma endothelin-1 in primary pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-469.

9. Olschewski H., Galie N., Ghofrani H et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. Proc Am Thorac Soc 2006;3:A728.

10. Cheng J.W. Ambrisentan for the Management of Pulmonary Arterial Hypertension. Clinical Therapeutics 2008; Vol. 30 (5):825-832.

11. Oudiz R., Badesch D., Rubin L. ARIES-E: Long-term safety and efficacy of ambrisentan in pulmonary arterial hypertension. Chest 2007;132:474a.

12. Elshaboury S.M., Anderson J.R. Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes. Patient Preference and Adherence 2013;7:401-409.

13. Vachiéry J.L., Hoeper M.M., Paruchuru P., et al. Pulmonary Arterial Hypertension in a Contemporary Drug Registry: The VOLT study. 3d SSWC., 2014. poster 191.